Characterizing the genetic architecture of drug response using gene-context interaction methods

Area of Science:

• Pharmacogenomics
• Clinical Genetics
• Drug Response

Background:

• Understanding factors influencing drug treatment response is crucial in clinical research.
• The impact of common genetic variations on drug response is not well understood.
• Large biobanks offer opportunities to investigate genetic influences on medication efficacy and side effects.

Purpose of the Study:

• To develop a framework for studying the genetic architecture of treatment response to common drugs.
• To quantify the heritability of response to statins, metformin, warfarin, and methotrexate.
• To assess the impact of genetic variation on drug response and the clinical utility of polygenic scores.

Main Methods:

• Utilized a large biobank (UK Biobank) to analyze genetic variation and treatment response.
• Quantified heritability for specific drug responses and side effects.
• Identified and replicated genes modifying drug response.
• Evaluated polygenic score accuracy in relation to treatment status.

Main Results:

• Genetic variation significantly modifies statin response, impacting LDL cholesterol, hemoglobin A1c, and blood glucose levels.
• Heritability estimates for statin effects on LDL cholesterol, HbA1c, and glucose were 9%, 10%, and 11%, respectively.
• Dozens of genes influencing drug response were identified and validated.
• Polygenic score accuracy demonstrated a 2-fold variation based on treatment status.

Conclusions:

• Common genetic variation plays a substantial role in modulating response to widely prescribed medications.
• Identified genes provide new targets for understanding pharmacogenomic mechanisms.
• Standard polygenic scores may underperform in clinical settings due to treatment interactions, necessitating context-specific models.